Cognitive Reserve as a Modifier of Clinical Expression in Chronic Traumatic Encephalopathy: A Preliminary Examination
Publication: The Journal of Neuropsychiatry and Clinical Neurosciences
Abstract
This study conducted a preliminary examination on cognitive reserve (CR) as a modifier of symptom expression in subjects with autopsy-confirmed chronic traumatic encephalopathy (CTE). The sample included 25 former professional football players neuropathologically diagnosed with CTE stage III or IV. Next of kin interviews ascertained age at cognitive and behavioral/mood symptom onset and demographic/athletic characteristics. Years of education and occupational attainment defined CR. High occupational achievement predicted later age at cognitive (p=0.02) and behavioral/mood (p=0.02) onset. Education was not an individual predictor. These preliminary findings suggest that CR may forestall the clinical manifestation of CTE.
Chronic traumatic encephalopathy (CTE) is a neurodegenerative disease associated with exposure to repetitive head impacts (RHI) and is uniquely characterized by a perivascular deposition of hyperphosphorylated tau (p-tau) at the sulcal depths.1–3 Although clinical research criteria for the in vivo diagnosis of CTE have been proposed,4 currently CTE can only be diagnosed based on neuropathological examination using recently defined criteria.1,3 The clinical presentation of CTE is heterogeneous and manifests as two variants (or a mixed combination): 1) initial behavioral/mood changes at a mean age of approximately 35, with later progression to cognitive deficits, and/or 2) initial cognitive impairment at a mean age of approximately 60, progressing to dementia.5
Age at symptom onset in CTE is variable, even in cases with similar neuropathological severity.5 One factor that may affect age at onset in CTE is cognitive reserve (CR). The CR theory posits that individuals with high reserve enlist pre-existing cognitive processes or compensatory strategies to cope with neuropathological insult.6 CR has been theorized to account for interindividual variability in the clinical course of normative aging and Alzheimer’s disease (AD), with higher CR associated with delayed onset of cognitive impairment and incident dementia.7,8 Although CR has traditionally been linked to cognitive impairment in AD, CR has been associated with reduced behavioral disturbances in frontotemporal dementia.9
There has been recent interest in the role of CR in the manifestation of CTE symptoms10 due to findings that higher education decreases vulnerability to cognitive dysfunction11 and facilitates recovery following traumatic brain injury (TBI).12 In our study examining the clinical presentation of neuropathologically confirmed cases of CTE without comorbid disease, two of three asymptomatic subjects with stage II CTE neuropathology had advanced graduate degrees (the third subject was 17 years old and had stage I CTE), raising the possibility of a CR effect in CTE.5 No study has empirically tested the role of CR in the clinical expression of CTE. This study conducted a preliminary examination on the association between CR (operationalized by years of education and occupational attainment) and age at reported cognitive and behavioral/mood symptom onset in former professional American football players with neuropathologically confirmed CTE. The sample was restricted to subjects with stage III or IV CTE disease severity in order to limit differences in age at symptom onset due to variability in neuropathological severity. We hypothesized that higher occupational attainment and greater years of education would predict later symptom onset.
Methods
Subjects
The sample included former professional American football players neuropathologically diagnosed with stage III or IV CTE. The former professional football players’ brains were donated to the Boston University-Veteran’s Affairs-Concussion Legacy Foundation Brain Bank. Brain donation was part of ongoing research at the Boston University Alzheimer’s Disease and CTE Center examining the neuropathology and clinical symptoms of deceased individuals with a history of RHI exposure, with specific funding from a National Institutes of Health-funded U01 project, titled “Understanding Neurologic Injury and Traumatic Encephalopathy (UNITE).” A detailed description of UNITE has been outlined elsewhere.13 Brain tissue was obtained through two methods: 1) following death, next of kin consented to donation of the subject’s brain and spinal cord, which in many instances was facilitated through community outreach, or 2) prior to death, subjects agreed to donate their brain and spinal cord through the project’s Brain Donation Registry. To optimize external validity and reduce ascertainment bias, inclusion criteria were broad and included only a history of RHI exposure. Brain donors were excluded for poor brain and spinal cord specimen quality.
Next of kin provided written informed consent for participation and brain donation at Boston University’s Alzheimer’s Disease Center. The institutional review boards (IRB) at Boston University Medical Center (BUMC) and the Edith Nourse Rogers Memorial Veteran’s Hospital (Bedford, MA) approved brain donation procedures. The BUMC IRB approved postmortem clinical record review, interviews with family members, and neuropathological evaluation.
Retrospective Next of Kin Interviews
Retrospective postmortem telephone interviews and online surveys with next of kin were conducted to ascertain clinical, demographic, and athletic characteristics of the decedent. See Mez et al.13 for a detailed description of the clinical evaluations used for data collection. Briefly, data relevant to the current study were obtained through semistructured and unstructured clinical interviews, as well as an online survey with next of kin. Informants completed the telephone interviews and online surveys individually or as a group (e.g., with other family members). To facilitate informant reliability, all informants reported on their relationship with the brain donor. The online survey asks about the brain donors’ demographic information (e.g., educational and occupational attainment), athletic characteristics (e.g., type of sport played, position level, duration of football played, age first started playing football), and military history. Telephone interviews with next of kin were performed by behavioral neurologists and neuropsychologists trained to assess RHI and clinical manifestations of neurodegenerative diseases. Here, semistructured questions were first asked to obtain detailed demographic, psychosocial, athletic, medical, psychiatric, and traumatic brain injury history. The clinician then led an unstructured interview to characterize the nature and course of symptoms (including age at symptom onset). Interviewers were blind to the results of the neuropathological examination, and informants were interviewed before receiving the neuropathological results.
Through the above procedures, we ascertained age at onset for cognitive (e.g., episodic memory impairment, executive dysfunction), behavioral (e.g., explosivity, impulsivity, disinhibition), and mood (e.g., depression, apathy) symptoms. Behavioral and mood symptoms were combined (behavioral/mood) for consistency with clinical research criteria.4 The earliest age at symptom onset was used to resolve discrepancies.
Cognitive Reserve
The above described methods also ascertained years of education and occupational attainment. Both variables served as proxies for CR. These variables were chosen based on epidemiological evidence in AD that shows both proxies are robust markers of reserve.8 To ascertain occupational attainment, next of kin reported the occupation(s) of the subject. Subjects who were students at the time of death were excluded from analyses. Based on occupational category, we classified subjects as high or low using U.S. Department of Labor’s Dictionary of Occupational Titles (DOT).14 Similar methods for classifying level of occupational attainment have been used in previous CR studies among other neurological populations.8,15 High attainment is defined as professional, technical, and managerial positions (DOT codes 0–1). Examples of these occupations include architect, engineer, meteorologist, teacher, professional athlete, general contractor, and service industry (and other industry) managers and officials, to name a few. Low attainment is defined as clerical/sales, agricultural/fishery/forestry, processing, machine trades, bench work, and structural occupations (DOT codes 2–8). Examples of these jobs include secretary, domestic service, food and beverage preparation and service, sales, painter, inspector, and assembler. There was one subject who fell in the Miscellaneous Occupations category (DOT code 9), and this subject was classified into the low occupational attainment group due to similarities to other types of occupations listed in DOT codes 2–8. In the case of multiple occupations, the highest level attained was used. Table 1 provides a breakdown of the occupational status of the sample according to the U.S. Department of Labor’s DOT.
| DOT Division | Attainment Classification | N |
|---|---|---|
| Professional, technical, and managerial occupations | High | 16 |
| Clerical and sales | Low | 4 |
| Service occupations | Low | 3 |
| Structural work | Low | 1 |
| Miscellaneous occupations | Low | 1 |
Pathological Diagnosis of CTE
Methodological procedures for pathological processing and evaluation are published elsewhere.16,17 In brief, brains were hemisected; one half was sectioned and frozen, and the other was fixed in periodate-lysine-paraformaldehyde for at least three weeks. The fixed tissue was dissected and processed into paraffin sections of multiple brain regions and comprehensively evaluated for neurodegenerative disease. The neuropathological diagnosis of CTE was made using neuropathological criteria recently defined by an NINDS/National Institute of Brain Imaging and Behavior (NIBIB) consensus panel.3 CTE pathological severity was graded using a four-stage classification system based on the extent and severity of tau pathology (stage I being least severe and stage IV being most severe).1,18 As described previously, the sample was restricted to stage III and IV CTE disease severity. Neuropathologists were blind to all clinical data. The study cohort included all subjects with available neuropathological diagnoses.
To minimize confound due to comorbid neuropathological disease, the final sample analyzed excluded subjects who had significant comorbid neuropathology for another neurodegenerative disease or acute catastrophic brain injury. Specifically, AD, diffuse Lewy body disease, frontotemporal lobar degeneration, motor neuron disease, prion disease, and corticobasal degeneration were excluded.
Statistical Analyses
The sample of 78 former American professional football players with stage III or IV CTE was reduced to 25 following several iterative exclusions to limit differences across subjects in athletic and RHI exposure and increase generalizability to CTE. First, 32 were excluded based on neuropathological criteria, including those with significant comorbid neuropathology (as described above). Second, 17 were excluded due to history of participation in another sport. Lastly, four cases were excluded due to missing data.
Independent samples t tests and chi-square analyses were conducted to determine between occupational group (high vs. low) differences on sample characteristics. Because occupational attainment and years of education may represent unique aspects of CR 19, they were examined independently. For occupational attainment and years of education, two separate linear regression analyses examined their association with age at cognitive and behavioral/mood symptom onset. Block 1 included number of years of football played in order to account for interindividual differences in RHI exposure. In separate models, block 2 included years of education and occupational attainment (1=high; 0=low). To clarify effects for the CR indices that emerged as significant, analysis of covariance (that accounted for duration of play) examined Bonferroni-adjusted estimated marginal mean differences on age at cognitive and behavioral/mood symptom onset.
Results
Sample Characteristics
Table 2 presents sample characteristics. Of the 25 subjects, 24 had cognitive and behavioral/mood symptoms, and one had only cognitive symptoms. The one subject with only cognitive symptoms was thus not included in analyses examining age at behavioral/mood symptom onset. Average age at symptom onset was 56.44 years (SD=14.42) for cognitive symptoms and 47.50 years (SD=16.45) for behavioral/mood symptoms. Eleven subjects had initial behavioral/mood symptoms, nine initial cognitive symptoms, and the remaining subjects had the same age at onset for cognitive and behavioral/mood symptoms. All but two subjects were reported to have had a progressive symptom course; one subject reportedly had a stable course, and another had a stepwise course.
| Characteristic | Total Sample (N=25) | High Occupational Attainment (N=16) | Low Occupational Attainment (N=9) | p |
|---|---|---|---|---|
| Demographic | ||||
| Age at death, mean (SD) (years) | 65.00 (14.07) | 67.75 (13.51) | 60.11 (14.47) | 0.20 |
| Race, N (%), white | 16 (64.0) | 9 (56.3) | 7 (77.8) | 0.28 |
| Education, mean (SD) (years) | 15.70 (1.22) | 15.75 (1.48) | 15.61 (0.60) | 0.79 |
| Military, N (%), yes | 8 (32.0) | 5 (31.3) | 3 (33.3) | 0.92 |
| Athletic | ||||
| Football primary position, N (%) | – | |||
| Lineman (OL/DL) | 10 (40.0) | 5 (31.3) | 5 (55.6) | |
| Linebacker | 2 (8.0) | 1 (6.3) | 1 (11.1) | |
| Defensive back/safety | 3 (12.0) | 3 (18.8) | 0 | |
| Running back | 7 (28.0) | 7 (43.8) | 0 | |
| Quarterback | 1 (4.0) | 0 | 1 (11.1) | |
| Other/multiple | 2 (8.0) | 0 | 2 (22.2) | |
| Duration of play, mean (SD) (years) | 19.24 (3.27) | 19.69 (2.73) | 18.44 (4.13) | 0.37 |
| CTE | ||||
| CTE stage, N (%) | 0.42 | |||
| III | 14 (56.0) | 8 (50.0) | 6 (66.7) | |
| IV | 11 (44.0) | 8 (50.0) | 3 (33.3) |
Cognitive Reserve and Age at Symptom Onset
Regression analyses controlling for duration of football played examined the association between occupational attainment and years of education with age at cognitive and behavioral/mood symptom onset. Block 1 of the models predicted age at onset for cognitive (p=0.004) but not behavioral/mood symptoms (p=0.76). After controlling for duration of football play, occupational attainment predicted age at cognitive (p=0.02) and behavioral/mood symptom onset (p=0.02; see Table 3). Greater occupational attainment correlated with later onset of symptoms. Bonferroni-adjusted estimated marginal mean differences (which accounted for duration of play) showed symptom onset began more than 10 years earlier in subjects with low occupational attainment compared with those with high occupational attainment (cognitive symptom onset: mean, SE for low occupational attainment=48.80, 3.72; high occupational attainment=60.74, 2.78, p=0.02; behavioral/mood symptom onset: mean, SE for low occupational attainment=37.37, 5.09; high occupational attainment=53.58, 3.92, p=0.02). Years of education was not a significant individual predictor for either symptom profile (p>0.05).
| Item | Analysis | |||||||
|---|---|---|---|---|---|---|---|---|
| Age at cognitive impairment onset | ||||||||
| β | b | SE ba | F | ∆F | R2 | ∆R2 | 95% CI for unstandardized b | |
| Block 1 | – | – | 10.04** | – | 0.30 | – | ||
| Duration of play (years) | –0.55** | –2.43 | 0.77 | – | – | – | – | –4.02 to –0.84 |
| Block 2 | – | – | 9.47** | 6.50* | 0.46 | 0.16 | ||
| Occupational attainment (1=high; 0=low) | 0.41* | 11.94 | 4.68 | – | – | – | – | 2.23 to 21.65 |
| Age at behavioral/mood symptom onset | ||||||||
| β | b | SE ba | F | ∆F | R2 | ∆R2 | 95% CI for unstandardized b | |
| Block 1 | – | – | 0.09 | – | 0.004 | – | ||
| Duration of play (years) | –0.07 | –0.32 | 1.05 | – | – | – | – | –2.49 to 1.85 |
| Block 2 | – | – | 3.19 | 6.26* | 0.23 | 0.23 | ||
| Occupational attainment (1=high; 0=low) | 0.49* | 16.20 | 6.48 | – | – | – | – | 2.73 to 29.67 |
a
SE b=standard error of unstandardized beta coefficient.
*
p<0.05; **p<0.01.
Discussion
The current study is the first to show that CR (i.e., occupational attainment) is associated with later symptom onset in a sample of former professional American football players with neuropathologically confirmed CTE stage III or IV. Occupational attainment and not years of education predicted age at symptom onset. These reserve proxies have been suggested to contribute to CR through independent paths,19 and the discrepant findings in this study may be related to the sampling of elite athletes. Educational attainment in this sample of mostly professional football players may be more reflective of athletic prowess. The limited variability in education may also explain non-significant effects. It is possible that occupational attainment may capture those subjects who continued academics post-football, those who remained mentally and physically active throughout their life, and/or those with a high innate intellect to achieve a high occupational status.
Higher CR was associated with onset of behavioral/mood and cognitive symptoms more than 10 years later in this sample of neuropathologically confirmed cases of CTE. The relationship between CR and cognitive outcomes is consistent with the AD literature that shows CR attenuates and delays onset of cognitive impairment.8 In addition to cognitive impairment, behavioral/mood symptoms are core features in CTE,4 and we found a significant CR effect for behavioral/mood disturbances in CTE. Because nearly all subjects had both cognitive and behavioral/mood symptoms, the distinct influence of CR on each symptom profile is unclear. One study found higher CR attenuates behavioral disturbances (e.g., disinhibition) in frontotemporal dementia,9 but minimal research has examined the relationship between CR and behavioral/mood symptoms. CR may mitigate the clinical phenotype associated with a specific neurodegenerative pathology, even if it is not cognitive in nature.
CTE is characterized pathologically by an accumulation of p-tau in neurons and astroglia distributed around small blood vessels at the cortical sulcal depths and in an irregular pattern.1–3 As the disease progresses, p-tau accumulates in widespread cortical regions, medial temporal lobe structures, the diencephalon, and brainstem. In advanced disease, cortical atrophy is severe, and there is marked neuronal loss in the hippocampus.1–3 Other microscopic alterations include axonal loss and white matter degeneration, chronic neuroinflammation, microvascular dysintegrity, and TDP-43 inclusions. Amyloid beta is found in approximately 50% of CTE cases and associated with age and the APOE ε4 allele.20 The pathological substrates underlying behavioral/mood and cognitive changes in CTE are unknown, and may involve multiple pathologies, including regional axonal damage, neuronal loss, p-tau, and TDP-43 accumulation. Based on evidence in AD, CR may modulate the clinical effects related to the neuropathological load in CTE. In a sample of 130 older Catholic clergy who underwent autopsy, greater years of education diminished the negative impact of neuritic and diffuse plaques on cognition proximate to death.21 Past work among 165 autopsy subjects from the Rush Memory and Aging Project revealed that reduced neuronal reserve (neuronal density) in the locus coeruleus and brain stem neurofibrillary tangles (NFT) and Lewy bodies predicted rate of cognitive decline, even after controlling for pathologic burden elsewhere in the brain.22 Such findings are noteworthy given the brainstem, especially the locus coeruleus, raphe nuclei, and substantia nigra, show high NFT density in CTE.1 CR may also attenuate the impact of pathology on clinical expression in CTE. Investigation of CR using ex vivo neuropathological data has well-defined methodological limitations.23 Currently, we are conducting prospective studies with objective assessments proximate to death to formally test CR as a modulator of CTE pathology. In addition, CR may also attenuate the impact of RHI on the severity of cognitive impairment,24,25 and longitudinal research in living subjects work will examine this possibility using validated metrics of RHI exposure.26
Lastly, longer duration of football play correlated with earlier age at cognitive symptom onset. Duration of football play has been associated with CTE stage,1 and may thus be a critical marker of RHI exposure. Notably, we did not find a relationship between duration of football play and behavioral/mood symptom onset. Different types of RHI exposure (beyond duration; e.g., specific types of hits) may differentially contribute to symptom phenotypes. Moreover, the relationship between RHI and CTE is complex and, risk factors beyond RHI exposure, including genetics, are likely critical in the pathogenesis of CTE.
The current study is preliminary, and the generalizability of our findings is limited in several ways. Our study includes a restricted sample of deceased professional football players without any other sport history and with only neuropathologically diagnosed stage III or IV CTE. Although this methodology limits confound from differences in athletic and RHI exposure and increases generalizability to CTE, the external validity of our findings, in general, and to the larger contact sport athlete population, in particular, is limited. Once sample size permits, our findings will need to be replicated in a larger sample of former athletes with various sport (e.g., soccer) and athletic backgrounds (e.g., level played) who were neuropathologically diagnosed with CTE. Even though our study did not recruit brain donors based on the presence of symptoms, the sample may demonstrate selection bias because family members are more likely to donate if their loved ones were symptomatic. A recent study from the Mayo Clinic Jacksonville neurodegenerative disease brain bank reviewed medical records and brain tissue slides of more than 1,700 male brain donors and found that 21 of 66 contact sport athletes had evidence of CTE pathology.2 Their approach reduces ascertainment bias; thus, replication of our results in other non-CTE autopsy series would be a critical next step in the examination of a CR effect in CTE. Similarly, drawing upon other brain banks with data on sport participation history will allow for utilization of comparison (e.g., AD) and control groups (e.g., former non-contact sport professional athletes without RHI exposure) to better understand the role of CR in CTE.
Retrospective interviews introduce self-report biases (e.g., memory lapses, subjectivity). However, this approach has been shown to be reliable and valid in other dementia autopsy studies.27 We are currently conducting longitudinal studies in living former contact sport athletes who have agreed to brain donation, and, in the future, we will examine the relationship between antemortem CR and objective test data in subjects with neuropathologically confirmed CTE. There is a lack of consensus regarding the operationalization of CR.28 We chose educational and occupational attainment to define CR based on epidemiological evidence that they are robust markers of CR.8 Reliability and validity of these indicators in elite athletes is unclear. In particular, there are multiple potential confounds associated with the use of occupational attainment to define CR. First, occupational attainment may be biased by athletes who died at a young age. Second, low occupational attainment may be a consequence of CTE, particularly for those with earlier onset of symptoms, rather than low cognitive reserve. Beyond these limitations, the retrospective nature of the study design precluded detailed history of lifetime occupational status (e.g., degree of responsibility). Nevertheless, this study provides initial evidence for a possible CR effect in CTE, and this finding needs to be replicated with future, prospective research studies that incorporate other proxies of CR, such as socioeconomic status or engagement in social and intellectual activities. Estimated premorbid intelligence as a proxy for CR in CTE may be problematic due to the potential negative impact of childhood RHI on intellectual and brain development.29 Recent research highlights the potential utility of residual memory variance (i.e., residual variance in episodic memory after controlling for demographic factors and brain pathology) as a potential marker of CR 30. Our center is currently conducting prospective research to identify in vivo biomarkers of CTE (e.g., normal amyloid beta; elevated p-tau/tau ratio; PET tau specific ligands, e.g., [F-18]-T807), and once validated, we will utilize the residual memory variance approach (and others) to examine CR in subjects with “probable CTE.” Such longitudinal work will also be critical to elucidate the symptom course of CTE and whether CR attenuates decline.
Conclusions
This study provides initial evidence that high CR may forestall the clinical manifestation of CTE. Large prospective studies of subjects at high risk for CTE that employ other CR proxies (e.g., social and intellectual enrichment) and objective symptom assessments are needed to better characterize the role of CR in the interplay among RHI, CTE pathology, and symptom presentation.
Acknowledgments
The authors gratefully acknowledge the use of the resources and facilities at the Edith Nourse Rogers Memorial Veterans Hospital (Bedford, Mass.). The authors also gratefully acknowledge the help of all members of the Chronic Traumatic Encephalopathy Program at Boston University School of Medicine, the Boston VA, as well as the individuals and families whose participation and contributions made this work possible.
References
1.
McKee AC, Stern RA, Nowinski CJ, et al: The spectrum of disease in chronic traumatic encephalopathy. Brain 2013; 136:43–64
2.
Bieniek KF, Ross OA, Cormier KA, et al: Chronic traumatic encephalopathy pathology in a neurodegenerative disorders brain bank. Acta Neuropathol 2015; 130:877–889
3.
McKee AC, Cairns NJ, Dickson DW, et al: The first NINDS/NIBIB consensus meeting to define neuropathological criteria for the diagnosis of chronic traumatic encephalopathy. Acta Neuropathol 2016; 131:75–86
4.
Montenigro PH, Baugh CM, Daneshvar DH, et al: Clinical subtypes of chronic traumatic encephalopathy: literature review and proposed research diagnostic criteria for traumatic encephalopathy syndrome. Alzheimers Res Ther 2014; 6:68
5.
Stern RA, Daneshvar DH, Baugh CM, et al: Clinical presentation of chronic traumatic encephalopathy. Neurology 2013; 81:1122–1129
6.
Stern Y: What is cognitive reserve? Theory and research application of the reserve concept. J Int Neuropsychol Soc 2002; 8:448–460
7.
Stern Y: Cognitive reserve in ageing and Alzheimer’s disease. Lancet Neurol 2012; 11:1006–1012
8.
Stern Y, Gurland B, Tatemichi TK, et al: Influence of education and occupation on the incidence of Alzheimer’s disease. JAMA 1994; 271:1004–1010
9.
Linds AB, Kirstein AB, Freedman M, et al: Trajectories of behavioural disturbances across dementia types. Can J Neurol Sci 2015; 42:389–394
10.
Bigler ED, Stern Y: Traumatic brain injury and reserve. Handb Clin Neurol 2015; 128:691–710
11.
Kesler SR, Adams HF, Blasey CM, et al: Premorbid intellectual functioning, education, and brain size in traumatic brain injury: an investigation of the cognitive reserve hypothesis. Appl Neuropsychol 2003; 10:153–162
12.
Schneider EB, Sur S, Raymont V, et al: Functional recovery after moderate/severe traumatic brain injury: a role for cognitive reserve? Neurology 2014; 82:1636–1642
13.
Mez J, Solomon TM, Daneshvar DH, et al: Assessing clinicopathological correlation in chronic traumatic encephalopathy: rationale and methods for the UNITE study. Alzheimers Res Ther 2015; 7:62
14.
United States Department of Labor: Dictionary of occupational titles, 4th ed. Washington, Government Printing Office, 1991
15.
Ghaffar O, Fiati M, Feinstein A: Occupational attainment as a marker of cognitive reserve in multiple sclerosis. PLoS One 2012; 7:e47206
16.
Vonsattel JP, Amaya MdelP, Cortes EP, et al: Twenty-first century brain banking: practical prerequisites and lessons from the past: the experience of New York Brain Bank, Taub Institute, Columbia University. Cell Tissue Bank 2008; 9:247–258
17.
Vonsattel JP, Del Amaya MP, Keller CE: Twenty-first century brain banking. Processing brains for research: the Columbia University methods. Acta Neuropathol 2008; 115:509–532
18.
Stein TD, Alvarez VE, McKee AC: Chronic traumatic encephalopathy: a spectrum of neuropathological changes following repetitive brain trauma in athletes and military personnel. Alzheimers Res Ther 2014; 6:4
19.
Richards M, Sacker A: Lifetime antecedents of cognitive reserve. J Clin Exp Neuropsychol 2003; 25:614–624
20.
Stein TD, Montenigro PH, Alvarez VE, et al: Beta-amyloid deposition in chronic traumatic encephalopathy. Acta Neuropathol 2015; 130:21–34
21.
Bennett DA, Wilson RS, Schneider JA, et al: Education modifies the relation of AD pathology to level of cognitive function in older persons. Neurology 2003; 60:1909–1915
22.
Wilson RS, Nag S, Boyle PA, et al: Neural reserve, neuronal density in the locus ceruleus, and cognitive decline. Neurology 2013; 80:1202–1208
23.
Bennett DA, Arnold SE, Valenzuela MJ, et al: Cognitive and social lifestyle: links with neuropathology and cognition in late life. Acta Neuropathol 2014; 127:137–150
24.
Bernick C, Banks S: What boxing tells us about repetitive head trauma and the brain. Alzheimers Res Ther 2013; 5:23
25.
Wright MJ, Woo E, Birath JB, et al: An index predictive of cognitive outcome in retired professional American football players with a history of sports concussion. J Clin Exp Neuropsychol 2016; 38:561–571
26.
Montenigro PH, Alosco ML, Martin B, et al. Cumulative head impact exposure predicts later-life depression, apathy, executive dysfunction, and cognitive impairment in former high school and collegiate football players. 2016; Epub ahead of print.
27.
Barber R, Snowden JS, Craufurd D: Frontotemporal dementia and Alzheimer’s disease: retrospective differentiation using information from informants. J Neurol Neurosurg Psychiatry 1995; 59:61–70
28.
Harrison SL, Sajjad A, Bramer WM, et al: Exploring strategies to operationalize cognitive reserve: a systematic review of reviews. J Clin Exp Neuropsychol 2015; 37:253–264
29.
Anderson V, Catroppa C, Morse S, et al: Intellectual outcome from preschool traumatic brain injury: a 5-year prospective, longitudinal study. Pediatrics 2009; 124:e1064–e1071
30.
Zahodne LB, Manly JJ, Brickman AM, et al: Is residual memory variance a valid method for quantifying cognitive reserve? A longitudinal application. Neuropsychologia 2015; 77:260–266
Information & Authors
Information
Published In
History
Received: 8 March 2016
Revision received: 28 April 2016
Accepted: 13 May 2016
Published online: 19 August 2016
Published in print: Winter 2017
Authors
Funding Information
Department of Defense Peer Reviewed Alzheimer’s Research Program: DoD- PRARP #13267017
Department of Veterans Affairs, the Veterans Affairs Biorepository: CSP 501
U.S. Department of Defense10.13039/100000005: W81XWH-13-2-0064
National Institute on Aging10.13039/100000049: P30AG13846; supplement 0572063345–5, R01AG1649
National Institute of Neurological Disorders and Stroke10.13039/100000065: 1UO1NS086659–01, R01NS078337, R56NS078337
Supported by the National Institute of Neurological Disorders and Stroke (1UO1NS086659-01, R01NS078337, R56NS078337), the Department of Defense (W81XWH-13-2-0064), the Department of Veterans Affairs, the Veterans Affairs Biorepository (CSP 501), the National Institute of Aging Boston University Alzheimer’s Disease Center (P30AG13846; supplement 0572063345–5), the Department of Defense Peer Reviewed Alzheimer’s Research Program (DoD-PRARP #13267017), the National Institute of Aging Boston University Framingham Heart Study (R01AG1649), and the National Operating Committee on Standards for Athletic Equipment and the Concussion Legacy Foundation. This work was also supported by unrestricted gifts from the Andlinger Foundation, the WWE, and the NFL. Michael L. Alosco and research reported in this article are supported by the National Institutes of Health under grant 1F32NS096803-01.Dr. Goldstein is a paid consultant to Johnson & Johnson (New Brunswick, N.J.)/Janssen Research & Development, LLC (Raritan, N.J.), and Rebiscan, Inc. (Cambridge, Mass.); and he has received funding from the WWE and Ivivi Health Sciences. Dr. Nowinski is a member of the Mackey-White Committee of the NFL Players Association and receives fees for speaking at educational programs. Dr. Stern has received research funding from the NFL, the NFL Players Association, and Avid Radiopharmaceuticals, Inc. (Philadelphia); he is a member of the Mackey-White Committee of the NFL Players Association; he is a paid consultant to Athena Diagnostics/Quest Laboratories (Marlborough, Mass.), Amarantus BioScience Holdings, Inc. (San Francisco), and Avanir Pharmaceuticals, Inc. (Aliso Viejo, Calif.); he receives royalties for published neuropsychological tests from Psychological Assessment Resources, Inc. (Lutz, Fla.), as well as compensation from expert legal opinion. Dr. McKee has received funding from the NFL, WWE, and is a member of the Mackey-White Committee of the NFL Players Association. All other authors report no financial relationships with commercial interests.Metrics & Citations
Metrics
Citations
Export Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.
For more information or tips please see 'Downloading to a citation manager' in the Help menu.
View Options
View options
PDF/EPUB
View PDF/EPUBLogin options
Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.
Personal login Institutional Login Open Athens loginNot a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).